inv-101
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 8, 2020 (NCT04531150)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cannabinoid CB1 receptorINVERSE AGONIST
CNR1 inverse agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06938204 | Phase 1 | Apr 1, 2024 | Innovo Therapeutics, Inc. |
| NCT05844592 | Phase 1 | Apr 21, 2022 | Innovo Therapeutics, Inc. |
| NCT04531150 | Phase 1 | Sep 8, 2020 | Altasciences Company Inc., Inversago Pharma, Inversago Pharma Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innovo Therapeutics, Inc. | For profit | 2 | 2 | 1 | 2022 |
| Altasciences Company Inc. | For profit | 1 | 0 | 1 | 2020 |
| Inversago Pharma | For profit | 1 | 0 | 1 | 2020 |
| Inversago Pharma Inc. | For profit | 1 | 1 | 1 | 2020 |
4 organizations
Page 1 / 1